AP&T: 乙型肝炎核心相关抗原在预测肝移植术后乙型肝炎病毒复发中的作用

2019-09-07 不详 MedSci原创

乙型肝炎核心相关抗原(HBcrAg)是慢性乙型肝炎(CHB)患者肝硬化和肝细胞癌(HCC)发展的生物标志物。然而,肝移植(LT)后HBcrAg与HBV复发之间的关系尚不清楚。因此,本项研究旨在调查血清HBcrAg水平与LT后HBV复发的相关性,以评估LT前HBcrAg水平的预后作用。

背景
乙型肝炎核心相关抗原(HBcrAg)是慢性乙型肝炎(CHB)患者肝硬化和肝细胞癌(HCC)发展的生物标志物。然而,肝移植(LT)后HBcrAg与HBV复发之间的关系尚不清楚。因此,本项研究旨在调查血清HBcrAg水平与LT后HBV复发的相关性,以评估LT前HBcrAg水平的预后作用。

方法
本项回顾性队列研究纳入了357名接受LT治疗的CHB患者,随访中位数为36.6个月。研究人员分析了与HBV复发相关的标志物的单变量和多变量分析以及计算了时间依赖性接受者操作特征(ROC)曲线。

结果
LT后48例(13.4%)患者出现HBV复发。HBcrAg,可检测的HBV DNA,HCC和HCC复发与HBV复发有关。在多变量分析中,HBcrAg水平与HBV复发独立相关,HBcrAg水平与HBV复发事件之间的关系具有显着性和分级(HR:3.17 /单位; 95%CI:1.97-5.11; P <趋势<.001) 。此外,HBcrAg水平在通过时间依赖性ROC分析预测HBV复发方面优于HBV DNA水平。HBcrAg≥5.0log U / mL的患者5年累积复发率显着高于HBcrAg <5.0 log U / mL的患者(37.6%vs 6%,P  <.001); 调整后的风险比为5.27(95%CI 2.47-11.25,P  <.001)。

结论
血清HBcrAg水平升高与LT后CHB患者HBV复发风险独立相关。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1998983, encodeId=f32b19989838b, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Nov 28 23:47:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825706, encodeId=2e291825e067b, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Mon Jul 27 11:47:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351562, encodeId=660b1351562ae, content=<a href='/topic/show?id=74672339e92' target=_blank style='color:#2F92EE;'>#乙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23397, encryptionId=74672339e92, topicName=乙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 09 07:47:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623344, encodeId=18b21623344cf, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Mon Sep 09 07:47:00 CST 2019, time=2019-09-09, status=1, ipAttribution=)]
    2019-11-28 cy0324
  2. [GetPortalCommentsPageByObjectIdResponse(id=1998983, encodeId=f32b19989838b, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Nov 28 23:47:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825706, encodeId=2e291825e067b, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Mon Jul 27 11:47:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351562, encodeId=660b1351562ae, content=<a href='/topic/show?id=74672339e92' target=_blank style='color:#2F92EE;'>#乙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23397, encryptionId=74672339e92, topicName=乙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 09 07:47:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623344, encodeId=18b21623344cf, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Mon Sep 09 07:47:00 CST 2019, time=2019-09-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1998983, encodeId=f32b19989838b, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Nov 28 23:47:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825706, encodeId=2e291825e067b, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Mon Jul 27 11:47:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351562, encodeId=660b1351562ae, content=<a href='/topic/show?id=74672339e92' target=_blank style='color:#2F92EE;'>#乙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23397, encryptionId=74672339e92, topicName=乙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 09 07:47:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623344, encodeId=18b21623344cf, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Mon Sep 09 07:47:00 CST 2019, time=2019-09-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1998983, encodeId=f32b19989838b, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Nov 28 23:47:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825706, encodeId=2e291825e067b, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Mon Jul 27 11:47:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351562, encodeId=660b1351562ae, content=<a href='/topic/show?id=74672339e92' target=_blank style='color:#2F92EE;'>#乙型肝炎病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23397, encryptionId=74672339e92, topicName=乙型肝炎病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 09 07:47:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623344, encodeId=18b21623344cf, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Mon Sep 09 07:47:00 CST 2019, time=2019-09-09, status=1, ipAttribution=)]

相关资讯

Hepatology:重庆医科大学陈娟和黄爱龙教授课题组在乙型肝炎病毒研究方面取得系列成果

众所周知,慢性乙型肝炎病毒感染是我国最为重要的公共卫生问题之一。乙型肝炎病毒共价闭合环状 DNA(cccDNA)是病毒进入细胞后首先形成的产物,在肝细胞核内可形成微小染色体,作为HBV复制的中心,对乙型肝炎病毒的复制以及持续感染状态的建立具有十分重要的意义。

Hepatology: Pevonedistat一种乙型肝炎病毒的有效抑制剂

乙型肝炎病毒(HBV)感染是全世界主要的健康问题。为了预防HBV相关死亡,消除病毒蛋白被认为是HBV治疗的最终目标; 然而,目前可用的核苷(t)ide类似物很少实现这一目标,因为其并没有阻止来自附加型病毒共价闭合环状DNA(cccDNA)的病毒转录。

Gastroenterology:GS-4774联合替诺福韦可增加HBV感染者特性T细胞响应

研究发现接种疫苗可以增加CD8 T细胞在抗原作用下产生的IFNG、TNF和IL2的能力。虽然GS-4774不能降低患者HBsAg水平,但其对CD8 T细胞的强免疫刺激作用可能与其他抗病毒药物联合应用,提高抗病毒免疫应答

BMC Gastroenterology: 超声可以用来评估慢性病毒性肝炎患者的肝硬度和颈动脉弹性

本研究旨在探究慢性病毒性肝炎患者肝脏硬度与颈动脉弹性之间的关系。研究人员使用声辐射力脉冲(ARFI)技术来测量肝脏的硬度,并使用射频(RF)血管定量超声技术来测量颈总动脉弹性和血管功能的变化。并以此比较二者的关系。

Digest Dis Sci: HBV相关肝癌根治后的抗病毒治疗可降低肿瘤复发

我国中南大学湘雅医学院附属海口医院Zhang等近日完成的一项荟萃分析表明,接受根治性治疗后的HBV相关肝细胞癌(HCC)患者应用核苷(酸)类似物(NA)治疗,与应用安慰剂或不治疗相比,可以降低HCC早期复发的风险,提高患者的整体生存率。

BMC Gastroenterology:血清HBV RNA定量可用于监测慢性乙型肝炎感染的自然史

乙型肝炎病毒(HBV)RNA作为肝内共价闭合环状DNA(cccDNA)转录活性的替代生物标志物,乙型肝炎病毒(HBV)RNA可在慢性乙型肝炎病毒感染期间在病毒-宿主相互作用期间进化。慢性HBV感染自然过程中血清HBV RNA水平的分布情况尚不清楚。本研究的目的是评估CHB自然过程中HBV RNA的水平以及其区分HBV感染自然史的作用。